Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Although in vitro observations suggest that cross-presentation of antigens is mediated primarily by CD8alpha+ dendritic cells, in vivo analysis has been hampered by the lack of systems that selectively eliminate this cell lineage. We show that deletion of the transcription factor Batf3 ablated development of CD8alpha+ dendritic cells, allowing us to examine their role in immunity in vivo. Dendritic cells from Batf3-/- mice were defective in cross-presentation, and Batf3-/- mice lacked virus-specific CD8+ T cell responses to West Nile virus. Importantly, rejection of highly immunogenic syngeneic tumors was impaired in Batf3-/- mice. These results suggest an important role for CD8alpha+ dendritic cells and cross-presentation in responses to viruses and in tumor rejection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“appears essential for T cell-driven antitumor immunity (Hildner et al., 2008)”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hildner et al., 2008
In the citing paper
“Both DC1s and DC2s expressed the DC markers Batf3, Flt3, H2-Dmb2 and Zbtb46 (Meredith et al., 2012; Hildner et al., 2008;); DC1 expressed Fscn1 and Ly 75 (DEC-205) whereas DC2s expressed CD209a (DC- SIGN), Mgl2 (CD301b) and Cd24a (Figure 2B and Figure S2B).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hildner et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citationJung, S., Unutmaz, D., Wong, P., Sano, G.-I., De los Santos, K., Sparwasser, T., Wu, S., Vuthoori, S., Ko, K., Zavala, F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00365-5 · Cited by 1,773
Barnden, M. J., Allison, J., Heath, W. R., & Carbone, F. R. (1998) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.1998.00709.x · Cited by 1,489
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H.-W., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,455
Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,328
Steady-state and inflammatory dendritic-cell development
Shortman, K., & Naik, S. H. (2007) · Nature Reviews Immunology · doi:10.1038/nri1996 · Cited by 1,190
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Bevan, M. J. (1976) · The Journal of experimental medicine · doi:10.1084/jem.143.5.1283 · Cited by 956
Toll-like receptor 3 promotes cross-priming to virus-infected cells
Schulz, O., Diebold, S. S., Chen, M., Näslund, T. I., Nolte, M. A., Alexopoulou, L., Azuma, Y.-T., Flavell, R. A., Liljeström, P., & Reis e Sousa, C. (2005) · Nature · doi:10.1038/nature03326 · Cited by 921
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 605
Cited by
Items 301–400 of 1,008
Scott, C. L., Soen, B., Martens, L., Skrypek, N., Saelens, W., Taminau, J., Blancke, G., Van Isterdael, G., Huylebroeck, D., Haigh, J., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151715 · Cited by 154
“…et al., 2014). cDC1s, expressing XCR1 and usually CD103 and/ or CD8α, are functionally specialized in cross-presentation of antigens to CD8+ T cells (Hildner et al., 2008; Bachem et al., 2010; Haniffa et al., 2012). cDC2s express CD172a (signal regulatory protein α [SIRPα]) and usually CD11b or…”
Jones, A., Bourque, J., Kuehm, L., Opejin, A., Teague, R. M., Gross, C., & Hawiger, D. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.008 · Cited by 154
“To determine such roles of DEC205+CD8+ DCs in vivo, we used Batf3 / mice, characterized by reduced numbers of these DCs (Hildner et al., 2008).”
MethodInfluentialHeidkamp, G. F., Sander, J., Lehmann, C. H. K., Heger, L., Eissing, N., Baranska, A., Lühr, J. J., Hoffmann, A., Reimer, K. C., Lux, A., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aai7677 · Cited by 154
Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling
Han, C., Liu, Z., Zhang, Y., Shen, A., Dong, C., Zhang, A., Moore, C., Ren, Z., Lu, C., Cao, X., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0641-5 · Cited by 162
Tamburini, B. A., Burchill, M. A., & Kedl, R. M. (2014) · Nature Communications · doi:10.1038/ncomms4989 · Cited by 153
Tang, M., Diao, J., Gu, H., Khatri, I., Zhao, J., & Cattral, M. S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.11.053 · Cited by 152
Zuo, B., Zhang, Y., Zhao, K., Wu, L., Qi, H., Yang, R., Gao, X., Geng, M., Wu, Y., Jing, R., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01266-8 · Cited by 155
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance
Zavitsanou, A., Pillai, R., Yuan, H., Wu, W., Bartnicki, E., Karakousi, T. R., Rajalingam, S., Herrera, A. M., Karatza, A., Rashidfarrokhi, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113295 · Cited by 177
“Tissue resident dendritic cells consist of two subsets: Batf3-dependent CD103+/CD8+ DCs (cDC1) specialized in cross presenting antigens to CD8 T cells through class I major histocompatibility complex (MHC) pathway (53) and CD11b+ DCs (cDC2) which drive CD4+ helper T cell responses (54,55).”
BackgroundMechanisms regulating dendritic cell specification and development
Watowich, S. S., & Liu, Y. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00949.x · Cited by 148
“Moreover, Batf3 ⁄ ) mice lack virus-specific CD8 T-cell responses and show defective rejection of immunogenic tumors, suggesting antigen cross-presentation by resident CD8a DCs elicits CD8 cytotoxic T-cell responses to virus and tumors (94).”
BackgroundInfluentialImai, T., Kato, Y., Kajiwara, C., Mizukami, S., Ishige, I., Ichiyanagi, T., Hikida, M., Wang, J. O., & Udono, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108372108 · Cited by 174
“This latter process is called cross-presentation (2–4) and is especially important to ensure effective host defense against viral infection or malignant transformation (5).”
BackgroundSufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity
Morrison, A. H., Diamond, M. S., Hay, C. A., Byrne, K. T., & Vonderheide, R. H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918971117 · Cited by 147
“Moreover, therapeutic efficacy of αCD40/ ICB was completely ablated in Batf3 KO mice [which lack crosspresenting CD103 DCs (27)] (Fig.”
BackgroundSizing up the key determinants of the CD8+ T cell response
Tscharke, D. C., Croft, N. P., Doherty, P. C., & Gruta, N. L. L. (2015) · Nature reviews. Immunology · doi:10.1038/nri3905 · Cited by 176
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer
Hubert, M., Gobbini, É., Couillault, C., Manh, T. V., Doffin, A., Berthet, J., Rodriguez, C., Ollion, V., Kielbassa, J., Sajous, C., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aav3942 · Cited by 167
NK Cells in the Tumor Microenvironment
Guillerey, C. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_4 · Cited by 174
DC-Based Vaccines for Cancer Immunotherapy
Fu, C., Zhou, L., Mi, Q.-S., & Jiang, A. (2020) · Vaccines · doi:10.3390/vaccines8040706 · Cited by 146
Becker, A. M., Michael, D. G., Satpathy, A. T., Sciammas, R., Singh, H., & Bhattacharya, D. (2012) · Blood · doi:10.1182/blood-2011-06-364976 · Cited by 146
Rapid and Efficient Generation of Regulatory T Cells to Commensal Antigens in the Periphery
Nutsch, K., Chai, J. N., Ai, T. L., Russler-Germain, E., Feehley, T., Nagler, C. R., & Hsieh, C.-S. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.092 · Cited by 145
“(B) Loss of CD103+CD11b DCs does not decrease pTreg cells.”
CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection
Wennerberg, E., Spada, S., Rudqvist, N.-P., Lhuillier, C., Gruber, S., Chen, Q., Zhang, F., Zhou, X. K., Gross, S. S., Formenti, S. C., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0449 · Cited by 155
“cDC1, which cross-present tumor antigens to CD8 T cells, are essential for antitumor immune responses (11).”
BackgroundDysfunction of antigen processing and presentation by dendritic cells in cancer
Bandola-Simon, J., & Roche, P. A. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2018.03.025 · Cited by 144
Control of adaptive immunity by pattern recognition receptors
Carroll, S. L., Pasare, C., & Barton, G. M. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.014 · Cited by 170
Jackson, J. T., Hu, Y., Liu, R., Masson, F., D’Amico, A., Carotta, S., Xin, A., Camilleri, M., Mount, A. M., Kallies, A., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.163 · Cited by 163
Wculek, S. K., Amores-Iniesta, J., Conde-Garrosa, R., Khouili, S. C., Melero, I., & Sancho, D. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0565-5 · Cited by 143
A vaccine targeting resistant tumours by dual T cell plus NK cell attack
Badrinath, S., Dellacherie, M. O., Li, A. W., Zheng, S., Zhang, X., Sobral, M. C., Pyrdol, J. W., Smith, K. L., Lu, Y., Haag, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04772-4 · Cited by 156
From skin dendritic cells to a simplified classification of human and mouse dendritic cell subsets
Guilliams, M., Henri, S., Tamoutounour, S., Ardouin, L., Schwartz-Cornil, I., Dalod, M., & MALISSEN, B. (2010) · European Journal of Immunology · doi:10.1002/eji.201040498 · Cited by 171
Bergamaschi, C., Pandit, H., Nagy, B. A., Stellas, D., Jensen, S. M., Bear, J., Cam, M., Valentin, A., Fox, B. A., Felber, B. K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000599 · Cited by 141
STING licensing of type I dendritic cells potentiates antitumor immunity
Wang, J., Li, S., Wang, M., Wang, X., Chen, S., Sun, Z., Ren, X., Huang, G., Sumer, B. D., Yan, N., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adj3945 · Cited by 156
Van Hoecke, L., Van Lint, S., Roose, K., Van Parys, A., Vandenabeele, P., Grooten, J., Tavernier, J., De Koker, S., & Saelens, X. (2018) · Nature Communications · doi:10.1038/s41467-018-05979-8 · Cited by 141
Dendritic Cells and Cancer: From Biology to Therapeutic Intervention
Wylie, B., Macri, C., Mintern, J. D., & Waithman, J. C. (2019) · Cancers · doi:10.3390/cancers11040521 · Cited by 158
BATF3 programs CD8+ T cell memory
Ataide, M. A., Komander, K., Knöpper, K., Peters, A. E., Wu, H., Eickhoff, S., Gogishvili, T., Weber, J., Grafen, A., Kallies, A., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0786-2 · Cited by 149
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment
Gajewski, T. F., Fuertes, M., Spaapen, R., Zheng, Y., & Kline, J. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.11.013 · Cited by 139
“The necessity of CD8α+ dendritic cells for cross-priming of anti-viral CD8+ T cell responses supports a critical role for this DC subset in vivo [27].”
BackgroundRegulation of myelopoiesis by the transcription factor IRF8
Tamura, T., Kurotaki, D., & Koizumi, S.-I. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1761-9 · Cited by 158
“IRF8 also interacts with BATFs [6], and Batf3−/− mice lack CD8α+ cDCs [43].”
BackgroundLung dendritic cells induce migration of protective T cells to the gastrointestinal tract
Ruane, D., Brane, L., Reis, B. S., Cheong, C., Poles, J., Do, Y., Zhu, H., Velinzon, K., Choi, J.-H., Studt, N., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20122762 · Cited by 139
“To examine the effect of depleting CD103+ lung DCs, we used two systems: temporal (Langerin DTR; Kissenpfennig et al., 2005) and constitutive (Batf3/; Hildner et al., 2008).”
Absence of MHC class II on cDCs results in microbial-dependent intestinal inflammation
Loschko, J., Schreiber, H. A., Rieke, G. J., Esterházy, D., Meredith, M. M., Pedicord, V. A., Yao, K.-H., Caballero, S., Pamer, E. G., Mucida, D., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160062 · Cited by 139
“…adaptive immune function is exemplified by the fact that cDC depletion during viral and bacterial infection results in impaired T cell immunity and increased susceptibility to infection (Jung et al., 2002; Kas- sim et al., 2006; Hildner et al., 2008; Satpathy et al., 2013; Schreiber et al., 2013).”
BackgroundArnold, I. C., Mathisen, S., Schulthess, J., Danne, C., Hegazy, A. N., & Powrie, F. (2016) · Mucosal Immunology · doi:10.1038/mi.2015.65 · Cited by 138
“Instead, most colonic CD103þ DCs are CD11b and require the transcription factor Batf3 for their development.(30) Batf3 / mice therefore lack tissue-resident CD8aþ and CD103þ CD11b nonlymphoid DC subsets.”
MacLeod, M. K. L., McKee, A. S., David, A., Wang, J., Mason, R., Kappler, J. W., & Marrack, P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104588108 · Cited by 138
“B6 IL-4 reporter (4Get) mice were obtained from Dr. R. Locksley (University of California, San Francisco, CA), and Batf3 KO mice were obtained from Ken Murphy (Washington University, St. Louis, MO).”
BackgroundInfluentialDendritic Cells in Atherosclerosis: Evidence in Mice and Humans
Zernecke, A. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.303566 · Cited by 137
STING, DCs and the link between innate and adaptive tumor immunity
Vatner, R. E., & Janssen, E. M. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.12.001 · Cited by 148
“Studies of mice lacking IFNAR specifically on DCs or lacking Batf3-dependent DC populations demonstrated that the anti-tumor responses were dependent on cDC1-like DCs (Diamond et al., 2011; Hildner et al., 2008; Klarquist et al., 2014).”
BackgroundDendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response
Garris, C. S., & Luke, J. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1321 · Cited by 137
“This has been emphasized by Batf3 murine knockout systems, which manifest with cDC1 deficiency (25).”
BackgroundOba, T., Long, M. D., Keler, T., Marsh, H. C., Minderman, H., Abrams, S. I., Liu, S., & Ito, F. (2020) · Nature Communications · doi:10.1038/s41467-020-19192-z · Cited by 147
The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy
Cueto, F. J., & Sancho, D. (2021) · Cancers · doi:10.3390/cancers13071525 · Cited by 148
“These Batf3−/− mice fail at controlling the development of highly immunogenic tumors, similar to Rag1−/− mice that lack mature lymphocytes [8].”
Backgroundvan Dinther, D., Veninga, H., Iborra, S., Borg, E. G. F., Hoogterp, L., Olesek, K., Beijer, M. R., Schetters, S. T. T., Kalay, H., García-Vallejo, J. J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.021 · Cited by 148
“To investigate the requirement of cross-presenting DCs to present Ags bound by CD169+ macro- phages, we used BATF3-deficient mice, which contain significantly decreased numbers of cross-presenting CD8a+ DCs, but do contain normal frequencies of CD169+ macrophages (Figures S1A and S1B) (Hildner et al., 2008).”
BackgroundEmerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Wang, Y., Johnson, K. C. C., Gatti-Mays, M. E., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01335-y · Cited by 138
Bispecific dendritic-T cell engager potentiates anti-tumor immunity
Itai, Y. S., Barboy, O., Salomon, R., Bercovich, A., Xie, K., Winter, E. E., Shami, T., Porat, Z., Erez, N., Tanay, A., et al. (2024) · Cell · doi:10.1016/j.cell.2023.12.011 · Cited by 150
RIG-I activation is critical for responsiveness to checkpoint blockade
Heidegger, S. M., Wintges, A., Stritzke, F., Bek, S., Steiger, K., Koenig, P.-A., Göttert, S., Engleitner, T., Öllinger, R., Nedelko, T., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aau8943 · Cited by 142
Holíček, P., Guilbaud, E., Klapp, V., Truxová, I., Špíšek, R., Galluzzi, L., & Fucikova, J. P. (2023) · Immunological Reviews · doi:10.1111/imr.13272 · Cited by 159
Cross-priming in cancer immunology and immunotherapy
Luri‐Rey, C., Teijeira, Á., Wculek, S. K., de Andrea, C. E., Herrero, C., López‐Janeiro, Á., Rodriguez-Ruiz, M. E., Heras‐Murillo, I., Aggelakopoulou, M., Berraondo, P., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00785-5 · Cited by 165
Daffis, S., Suthar, M. S., Szretter, K. J., Gale, M., & Diamond, M. S. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000607 · Cited by 133
“immune responses [34], we evaluated IFN and ISG responses in”
MethodOntogeny and function of murine epidermal Langerhans cells
Kaplan, D. H. (2017) · Nature Immunology · doi:10.1038/ni.3815 · Cited by 132
Immunotherapeutic effects of intratumoral nanoplexed poly I:C
Aznar, M. A., Planelles, L., Perez-Olivares, M., Molina, C., Garasa, S., Etxeberría, I., Perez, G., Rodriguez, I., Bolaños, E., Lopez-Casas, P., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0568-2 · Cited by 132
“ment of BATF-3-dependent conventional type-I dendritic cells (cDC1) [33].”
BackgroundInfluentialJin, F., Qi, J., Liu, D., You, Y., Shu, G., Du, Y., Wang, J., Xu, X., Ying, X., Ji, J., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.07.021 · Cited by 138
Human and Mouse Mononuclear Phagocyte Networks: A Tale of Two Species?
Reynolds, G., & Haniffa, M. A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00330 · Cited by 153
“The CDP-derived cells are defined by their dependence on specific transcription factors (TFs): cDC1 are Batf3-dependent, cDC2 are Irf4-dependent, and pDC are E2-2-dependent (61).”
BackgroundInfluentialLung dendritic cells at the innate-adaptive immune interface
Condon, T. V., Sawyer, R. T., Fenton, M. J., & Riches, D. W. H. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0311134 · Cited by 132
“Mice deficient in the transcription factor Batf3 are deficient in lung CD103 DCs and LN resident CD8 DCs, and Batf3 / mice exhibit reduced priming of CD8 T cells after Sendai virus infection, as well as increased pulmonary inflammation [94, 95].”
BackgroundCis and Trans Effects of Human Genomic Variants on Gene Expression
Bryois, J., Buil, A., Evans, D. M., Kemp, J. P., Montgomery, S. B., Conrad, D. F., Ho, K. M., Ring, S., Hurles, M., Deloukas, P., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004461 · Cited by 132
“The cis-eQTL of BATF3, a gene involved in the differentiation of CD8a dendritic cells and IL17-producing T helper cells [20,21], is a trans-eQTL of 14 genes, distributed on 8 chromosomes.”
BackgroundHeger, L., Balk, S., Lühr, J. J., Heidkamp, G. F., Lehmann, C. H. K., Hatscher, L., Purbojo, A., Hartmann, A., Garcia-Martin, F., Nishimura, S.-I., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00744 · Cited by 131
Bommareddy, P. K., Aspromonte, S., Zloza, A., Rabkin, S. D., & Kaufman, H. L. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aau0417 · Cited by 132
“11 of 13 The Batf3+ (CD8+CD103+) DC population was initially identified as critical for priming antiviral CD8+ T cell responses (16).”
Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity
Giampazolias, E., Schulz, O., Lim, K. H. J., Rogers, N. C., Chakravarty, P., Srinivasan, N., Gordon, O., Cardoso, A., Buck, M. D., Poirier, E. Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.021 · Cited by 132
“…models, absence of cDC1s prevents CD8+ T celldriven regression of immunogenic tumors and curtails therapeutic responses to adoptive T cell transfer or checkpoint blockade inhibition (Broz et al., 2014; Hildner et al., 2008; Salmon et al., 2016; Sánchez-Paulete et al., 2016; Spranger et al., 2017).”
BackgroundInfluentialTrial watch: Dendritic cell (DC)-based immunotherapy for cancer
Laureano, R. S., Sprooten, J., Vanmeerbeerk, I., Borràs, D., Govaerts, J., Naulaerts, S., Berneman, Z. N., Beuselinck, B., Bol, K. F., Borst, J. G., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2096363 · Cited by 144
Oral Antibiotic Treatment of Mice Exacerbates the Disease Severity of Multiple Flavivirus Infections
Thackray, L. B., Handley, S. A., Gorman, M. J., Poddar, S., Bagadia, P., Briseño, C. G., Theisen, D. J., Tan, Q., Hykes, B. L., Lin, H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.001 · Cited by 130
“Cross-presentation by dendritic cells (DCs) contributes to the priming of WNV-specific CD8+ T cell responses (Hildner et al., 2008).”
BackgroundNF-κB–dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity
Ghislat, G., Cheema, A. S., Baudoin, E., Verthuy, C., Ballester, P. J., Crozat, K., Attaf, N., Dong, C., Milpied, P., Malissen, B., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg3570 · Cited by 130
“However, Batf3 is not exclusively expressed by cDC1s, and these mice display other phenotypes, including intrinsic defects in memory CD8+ T cells (24, 25), reduced numbers of cDC2s (14), and an increased frequency of regulatory T cells (26).”
BackgroundInnate and Adaptive Immune Functions of Peyer’s Patch Monocyte-Derived Cells
Bonnardel, J., Da Silva, C., Henri, S., Tamoutounour, S., Chasson, L., Montañana-Sanchis, F., Gorvel, J.-P., & Lelouard, H. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.067 · Cited by 129
“DN DCs and CD8a+ DCs produce IL12 in response to bacterial stimulation, while CD11b+ DCs produce IL-10 and IL-6 and induce IgA secretion in vitro (Iwasaki and Kelsall, 2001; Sato et al., 2003).”
BackgroundInfluentialVan Lint, S., Renmans, D., Broos, K., Goethals, L., Maenhout, S., Benteyn, D., Goyvaerts, C., Du Four, S., Van der Jeught, K., Bialkowski, L., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0163 · Cited by 130
“This finding is consistent with several studies showing that Batf-3 / mice, which lack CD8aþ cross-presenting DCs, fail to clear highly immunogenic tumors (8, 9).”
BackgroundResultOhta, T., Sugiyama, M., Hemmi, H., Yamazaki, C., Okura, S., Sasaki, I., Fukuda, Y., Orimo, T., Ishii, K. J., Hoshino, K., et al. (2016) · Scientific Reports · doi:10.1038/srep23505 · Cited by 130
Griffiths, K., Ahmed, M., Das, S., Gopal, R., Horne, W. T., Connell, T. D., Moynihan, K. D., Kolls, J. K., Irvine, D. J., Artyomov, M. N., et al. (2016) · Nature Communications · doi:10.1038/ncomms13894 · Cited by 132
Mittal, D., Vijayan, D., Putz, E. M., Aguilera, A. R., Markey, K. A., Straube, J., Kazakoff, S., Nutt, S. L., Takeda, K., Hill, G. R., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0341 · Cited by 130
“In particular, Batf3-deficient mice show impaired ability to crossprime cytotoxic T lymphocytes (CTL) against tumor antigens in immunogenic fibrosarcomas and lack virus-specific CTL responses to West Nile infection (7).”
BackgroundDifferential Intrasplenic Migration of Dendritic Cell Subsets Tailors Adaptive Immunity
Calabro, S., Liu, D., Gallman, A., Nascimento, M. S. L., Yu, Z., Zhang, T.-T., Chen, P., Zhang, B., Xu, L., Gowthaman, U., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.076 · Cited by 129
“In contrast, Batf3-dependent XCR1+CD8αα+ cDCs readily cross-present phagocytosed antigen on MHC class I (MHCI) to CD8+ T cells (den Haan et al., 2000; Hildner et al., 2008; Pooley et al., 2001; Schnorrer et al., 2006; Schulz and Reis e Sousa, 2002).”
InfluentialDetienne, S., Welsby, I., Collignon, C., Wouters, S., Coccia, M., Delhaye, S., Maele, L. V., Thomas, S., Swertvaegher, M., Detavernier, A., et al. (2016) · Scientific Reports · doi:10.1038/srep39475 · Cited by 135
Engineering interferons and interleukins for cancer immunotherapy
Holder, P. G., Lim, S. A., Huang, C., Sharma, P. A., Dagdas, Y. S., Bulutoglu, B., & Sockolosky, J. T. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114112 · Cited by 138
Schetters, S. T. T., Jong, W. S. P., Horrevorts, S. K., Kruijssen, L. J. W., Engels, S., Stolk, D. A., Daleke, M. H., García-Vallejo, J. J., Houben, D., Unger, W. W. J., et al. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.04.033 · Cited by 135
Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity
Noubade, R., Majri-Morrison, S. S., & Tarbell, K. V. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01014 · Cited by 146
“The critical role of cDC1s in anti-tumor immunity has been shown using mice deficient in basic leucine zipper transcription factor ATF-like 3 (Batf3), a transcription factor required for cDC1 differentiation (65).”
BackgroundMajor histocompatibility complex class I binding predictions as a tool in epitope discovery
Lundegaard, C., Lund, O., Buus, S., & Nielsen, M. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03300.x · Cited by 140
PU.1 Level-Directed Chromatin Structure Remodeling at the Irf8 Gene Drives Dendritic Cell Commitment
Schönheit, J., Kuhl, C., Gebhardt, M. L., Klett, F. F., Riemke, P., Scheller, M., Huang, G., Naumann, R., Leutz, A., Stocking, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.007 · Cited by 127
“1, SpiB, Tcf4 (E2-2), Batf3, Id2, and Irf8 (also known as interferon consensus sequence binding protein [ICSBP]) have been implicated in DC development (Watowich and Liu, 2010; Carotta et al., 2010; Schotte et al., 2004; Cisse et al., 2008; Hildner et al., 2008; Hacker et al., 2003).”
BackgroundWilliford, J.-M., Ishihara, J., Ishihara, A., Mansurov, A., Hosseinchi, P., Marchell, T. M., Potin, L., Swartz, M. A., & Hubbell, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aay1357 · Cited by 127
The tumor-draining lymph node as a reservoir for systemic immune surveillance
Delclaux, I., Ventre, K. S., Jones, D., & Lund, A. W. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.09.006 · Cited by 155
“Mice lacking cross-presenting cDCs (cDC1s) fail to activate CD8 + T cells and respond to immunotherapy [23,24].”
Baljon, J. J., Kwiatkowski, A. J., Pagendarm, H. M., Stone, P. T., Kumar, A., Bharti, V., Schulman, J. A., Becker, K. W., Roth, E. W., Christov, P. P., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c04471 · Cited by 136
Sinclair, C., Bommakanti, G., Gardinassi, L., Loebbermann, J., Johnson, M. J., Hakimpour, P., Hagan, T., Benitez, L., Todor, A., Machiah, D., et al. (2017) · Science · doi:10.1126/science.aaj2155 · Cited by 126
Belizaire, R., & Unanue, E. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908583106 · Cited by 125
“Multiple studies indicated that CD8 DCs are the principal cross-presenting APCs in vivo (38, 39).”
BackgroundLukens, M. V., Kruijsen, D., Coenjaerts, F. E. J., Kimpen, J. L. L., & van Bleek, G. M. (2009) · Journal of Virology · doi:10.1128/jvi.00452-09 · Cited by 125
Dai, P., Wang, W., Yang, N., Serna-Tamayo, C., Ricca, J. M., Zamarin, D., Shuman, S., Merghoub, T., Wolchok, J. D., & Deng, L. (2017) · Science Immunology · doi:10.1126/sciimmunol.aal1713 · Cited by 125
“Batf3-deficient mice are unable to reject highly immunogenic tumors (26).”
BackgroundInfluentialHuman mononuclear phagocyte system reunited
Haniffa, M. A., Bigley, V., & Collin, M. P. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.05.004 · Cited by 148
“The distinct developmental pathways of monocytes and DCs from hematopoietic stem cells (HSCs) were defined in mouse, showing that DCs arose independently, through progenitors with restricted DC potential, reliant on specific genes [36–42].”
BackgroundDendritic Cells: Arbiters of Immunity and Immunological Tolerance
Lewis, K. L., & Reizis, B. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007401 · Cited by 125
“The identification of transcription factor Batf3 as a “master regulator” of the CD8þ/ CD103þ subset strongly supports its unique genetic identity and functionality as a major Ag cross-presenting cell type (Hildner et al. 2008).”
BackgroundAntigen cross-presentation by dendritic cell subsets: one general or all sergeants?
Nierkens, S., Tel, J., Janssen, E. M., & Adema, G. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.02.007 · Cited by 132
Synthetic nanovaccines for immunotherapy
Luo, M., Samandi, L. Z., Wang, Z., Chen, Z. J., & Gao, J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.033 · Cited by 129
Selective inhibition of low-affinity memory CD8(+) T cells by corticosteroids
Tokunaga, A., Sugiyama, D., Maeda, Y., Warner, A. B., Panageas, K. S., Ito, S., Togashi, Y., Sakai, C., Wolchok, J. D., & Nishikawa, H. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20190738 · Cited by 124
Guilliams, M., & van de Laar, L. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00406 · Cited by 123
“August 2015 | Volume 6 | Article 4064 Frontiers in Immunology | www.frontiersin.org cDC2s, and pDCs in the mouse. cDC1s, but not cDC2s, require BATF3 (71, 73, 74), ID2 (28, 75, 76), NFIL3 (77), and IRF8 (28, 71, 78–80) for their development, while cDC2s, but not cDC1s, are dependent on RELB (81), RBPJ (82), and IRF4 (…”
Critical role for Sec22b-dependent antigen cross-presentation in antitumor immunity
Alloatti, A., Rookhuizen, D. C., Joannas, L., Carpier, J.-M., Iborra, S., Magalhaes, J. G., Yatim, N., Kozik, P., Sancho, D., Albert, M. L., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20170229 · Cited by 123
“The K. Murphy group (Hildner et al., 2008) has shown that certain subsets of crosspresenting DCs (i.e., Batf3dependent DCs) have a critical role in antiviral im mune responses and in the rejection of established solid tumors by CD8+ T cells.”
BackgroundZhang, X., Xiao, X., Lan, P., Li, J., Dou, Y., Chen, W., Ishii, N., Chen, S., Xia, B., Chen, K., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.052 · Cited by 134
“BATF3 is a transcription factor without known deacetylase activities (Hildner et al., 2008; Iacobelli et al., 2000).”
BackgroundSpecialized immune responses in the peritoneal cavity and omentum
Liu, M., Silva-Sánchez, A., Randall, T. D., & Meza‐Perez, S. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mir0720-271rr · Cited by 147
Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment
Zhu, S., Wang, Y., Tang, J., & Cao, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1074477 · Cited by 155
Guo, L., Wang, C., Qiu, X., Pu, X., & Chang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01052 · Cited by 122
The Role of FcRn in Antigen Presentation
Baker, K., Rath, T., Pyzik, M., & Blumberg, R. S. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00408 · Cited by 121
Dendritic cell recruitment and activation in autoimmunity
Sozzani, S., Prete, A. D., & Bosisio, D. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.07.012 · Cited by 126
The Varieties of Immunological Experience: Of Pathogens, Stress, and Dendritic Cells
Pulendran, B. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075049 · Cited by 121
Tuning the Tumor Myeloid Microenvironment to Fight Cancer
Jahchan, N. S., Mujal, A. M., Pollack, J. L., Binnewies, M., Sriram, V., Reyno, L., & Krummel, M. F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01611 · Cited by 120
Pulko, V., Liu, X., Krco, C. J., Harris, K. J., Frigola, X., Kwon, E. D., & Dong, H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900974 · Cited by 127
“Because CD8 DCs have a crucial role in cross-priming CTLs in vivo (37, 38, 41), selective up-regulation of B7-H1 by TLR3 ligand may add a negative regulator, which determines the extent of CD8 T cell responses.”
BackgroundInvestigating Evolutionary Conservation of Dendritic Cell Subset Identity and Functions
Vu Manh, T.-P., Bertho, N., Hosmalin, A., Schwartz-Cornil, I., & Dalod, M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00260 · Cited by 119
“achieved in mice XCR1 cDC are critical for anti-tumoral responses in mice (72, 121, 152, 153).”
BackgroundChappell, C. P., Draves, K. E., Giltiay, N. V., & Clark, E. A. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120774 · Cited by 145
Found in translation: the human equivalent of mouse CD8+ dendritic cells
Villadangos, J. A., & Shortman, K. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100985 · Cited by 120
Dendritic Cells Coordinate the Development and Homeostasis of Organ-Specific Regulatory T Cells
Leventhal, D. S., Gilmore, D. C., Berger, J. M., Nishi, S., Lee, V., Malchow, S., Kline, D. E., Kline, J. P., Griend, D. J. V., Huang, H., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.025 · Cited by 120
“Batf3 / mice exhibit a deficiency of CD8a cDCs in the thymus (Figures 3E, S3H, and S3I) and secondary lymphoid organs (Hildner et al., 2008), which allowed us to test the requirement for CD8a cDCs in orchestrating Treg cell development.”
Iwata, A., Durai, V., Tussiwand, R., Briseño, C. G., Wu, X., Grajales‐Reyes, G. E., Egawa, T., Murphy, T. L., & MURPHY, K. M. M. (2017) · Nature Immunology · doi:10.1038/ni.3714 · Cited by 139
Human Dendritic Cell Subsets, Ontogeny, and Impact on HIV Infection
Rhodes, J. W., Tong, O., Harman, A. N., & Turville, S. G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01088 · Cited by 136
Metadata
- Authors
- Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., Schreiber, R. D., Murphy, T. L., & Murphy, K. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
- Corresponding author
- Murphy, Kenneth M.
- ORCID
- Venue
- Science
- Published
- 2008-11-14
- Volume
- 322
- Issue
- 5904
- Pages
- 1097-1100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2756611
- OpenAlex
- W2046505430
- Cited by
- 2,081
- References
- 29
- Citations by year
- 2026: 117 · 2025: 150 · 2024: 142 · 2023: 129 · 2022: 161 · 2021: 167 · 2020: 182 · 2019: 129 · 2018: 109 · 2017: 133 · 2016: 115 · 2015: 105 · 2014: 92 · 2013: 89 · 2012: 90
- FWCI
- 23.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- Batf3, CD8α+ dendritic cells, cross-presentation, West Nile virus, tumor rejection, dendritic cell development, transcription factors, antitumor immunity
- MeSH terms
- Animals, Antibodies, Viral, Cytotoxicity, Immunologic, Dendritic Cells, Female, Fibrosarcoma, Lymphocyte Activation, Male, Mice, Inbred C57BL, Repressor Proteins, Spleen, T-Lymphocytes, Cytotoxic, West Nile Fever, West Nile virus, CD4-Positive T-Lymphocytes, CD8 Antigens, Adoptive Transfer, Cross-Priming, Basic-Leucine Zipper Transcription Factors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.